Today on the Daily Dive, we are joined by Adam Deffett, VP of Capital Markets for KetamineOne Capital (NEO: MEDI). Adam, joins us this afternoon to discuss the strategy behind Ketamine One and how it relates to recent acquisitions, the move to the NEO exchange, IVR therapies, and the future of the ketamine space as a whole.
KetamineOne Capital is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
Gold Price Is The US Dollar’s Enemy – The Daily Dive feat Russell Starr of Trillium Gold
Returning to the Daily Dive is Russell Starr of Trillium Gold (TSXV: TGM), whom sits...